Michael R. Bristow M.D., Ph.D.
Net Worth
Last updated:
What is Michael R. Bristow M.D., Ph.D. net worth?
The estimated net worth of Dr. Michael R. Bristow M.D., Ph.D. is at least $7,215,773 as of 4 Apr 2017. He owns shares worth $102,064 as insider, has earned $47,949 from insider trading and has received compensation worth at least $7,065,760 in ARCA biopharma, Inc..
What is the salary of Michael R. Bristow M.D., Ph.D.?
Dr. Michael R. Bristow M.D., Ph.D. salary is $441,610 per year as Co-Founder, Pres, Chief Executive Officer & Director in ARCA biopharma, Inc..
How old is Michael R. Bristow M.D., Ph.D.?
Dr. Michael R. Bristow M.D., Ph.D. is 80 years old, born in 1945.
What stocks does Michael R. Bristow M.D., Ph.D. currently own?
As insider, Dr. Michael R. Bristow M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| ARCA biopharma, Inc. (ABIO) | Co-Founder, Pres, Chief Executive Officer & Director | 41,155 | $2.48 | $102,064 |
What does ARCA biopharma, Inc. do?
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Michael R. Bristow M.D., Ph.D. insider trading
ARCA biopharma, Inc.
Dr. Michael R. Bristow M.D., Ph.D. has made 8 insider trades between 2009-2017, according to the Form 4 filled with the SEC. Most recently he sold 720 units of ABIO stock worth $1,735 on 4 Apr 2017.
The largest trade he's ever made was exercising 1,069,290 units of ABIO stock on 25 Jan 2013. As of 4 Apr 2017 he still owns at least 41,155 units of ABIO stock.
ARCA biopharma key executives
ARCA biopharma, Inc. executives and other stock owners filed with the SEC:
- Dr. Michael R. Bristow M.D., Ph.D. (80) Co-Founder, Pres, Chief Executive Officer & Director
- Mr. Christopher D. Ozeroff (66) Senior Vice President, Gen. Counsel & Sec.
- Mr. Thomas A. Keuer (66) Chief Operating Officer